Article
Clearside Biomedical's axitinib injectable suspension phase 1/2a trial enrolls first patients
Author(s):
Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.
Related Videos
Related Content
